Beneficial Effects of novel Aureobasidium Pullulans strains produced Beta-1,3-1,6 Glucans on Interleukin-6 and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study

Autor: Kadalraja Raghavan, Nobunao Ikewaki, Vaddi Suryaprakash, K.S.J. Rao, Vidyasagar Devaprasad Dedeepiya, Samuel J. K. Abraham, Masaru Iwasaki, Senthilkumar Preethy, Gary A. Levy, Tohru Sonoda, Rajappa Senthilkumar
Rok vydání: 2021
Předmět:
Complementary Therapies
Male
beta-Glucans
Lymphocyte
Pilot Projects
Cytokine storm
Gastroenterology
Beta-glucan
D-Dimer
chemistry.chemical_compound
Coagulopathy
Beta Glucans
chemistry.chemical_classification
biology
medicine.diagnostic_test
Standard treatment
General Medicine
Middle Aged
Immuno-modulation
Treatment Outcome
medicine.anatomical_structure
Erythrocyte sedimentation rate
Female
Cytokine Release Syndrome
medicine.medical_specialty
Aureobasidium
RM1-950
Adjunct treatment
Article
Fibrin Fibrinogen Degradation Products
Internal medicine
D-dimer
medicine
Humans
Immunologic Factors
Neutrophil to lymphocyte ratio
Interleukin 6
Beta (finance)
Glucan
Pharmacology
IL-6
Interleukin-6
SARS-CoV-2
business.industry
COVID-19
biology.organism_classification
medicine.disease
COVID-19 Drug Treatment
Aureobasidium pullulans
chemistry
Dietary Supplements
biology.protein
Therapeutics. Pharmacology
business
CD8
Biomarkers
Zdroj: Biomedicine & Pharmacotherapy
Biomedicine & Pharmacotherapy, Vol 145, Iss, Pp 112243-(2022)
DOI: 10.1101/2021.08.09.21261738
Popis: Objective In this pilot clinical study, we report the beneficial effects of beta glucans derived from two strains AFO-202 and N-163 of a black yeast Aureobasidium pullulans on the biomarkers for cytokine storm and coagulopathy in COVID-19 patients. Methods A total of 24 RT-PCR positive COVID-19 patients were recruited and randomly divided into three groups (Gr): Gr. 1 control (n=8) – Standard treatment; Gr. 2: Standard treatment + AFO-202 beta glucan (n=8); and Gr. 3, Standard treatment + combination of AFO-202 and N-163 beta glucans (n=8) for 30 days. Results There was no mortality or requirement of ventilation of the subjects in any of the groups. There was a decrease in D-Dimer values (751 ng/ml to 143.89 ng/ml) and IL-6 values (7.395 pg/ml to 3.16 pg/ml) in Gr. 1 in 15 days but the levels increased to abnormal levels on day 30 (D-Dimer: 202.5 ng/ml; IL-6 55.37 pg/ml); which steadily decreased up to day 30 in groups 2 (D-dimer: 560.99 ng/dl to 79.615; IL-6: 26.18 pg/ml to 3.41 pg/ml) and 3 (D-dimer: 1614 ng/dl to 164.25 ng/dl; IL-6: 6.25 pg/ml to 0.5 pg/ml). The same trend was observed with ESR. LCR and LeCR increased while NLR decreased significantly in Gr. 3. CD4+ and CD8+ T cell count showed relatively higher increase in Gr.3. There was no difference in CRP within the groups. Conclusion As these beta glucans are well known food supplements with a track record for safety, larger multi-centric clinical studies are recommended to validate their use as an adjunct in the management of COVID-19 and the ensuing long COVID-19 syndrome.
Graphical Abstract
Databáze: OpenAIRE
Externí odkaz: